- Antifungal from F2G, Shionogi succeeds in Phase 3 studyF2G and Shionogi released positive Phase 3 data on Thursday morning, giving the companies a potentially clear path to approval for their antifungal drug. The companies said their treatment called…Endpoints · 1mo ago↗ source
- Kardigan raises $400M in IPO to back three clinical-stage cardio drugsMore evidence has arrived that biotech IPOs are alive and well: A cardiology drug developer with three clinical-stage candidates just secured $400 million for its Nasdaq debut slated for Thursday.…Endpoints · 1mo ago↗ source
- Biogen makes up to $1B deal for secretive anti-inflammatory biotechBiogen will pay as much as $1 billion — “predominantly” in milestone payments — to acquire a San Diego biotech that has disclosed little about its pipeline. The startup, RayThera, debuted last ye…